Winer, Eric S.
Safran, Howard
Karaszewska, Boguslawa
Bauer, Sebastian
Khan, Dilawar
Doerfel, Steffen
Burgess, Paul
Kalambakas, Stacey
Mostafa Kamel, Yasser
Forget, Frederic
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 6 April 2017
Revised: 1 August 2017
Accepted: 10 August 2017
First Online: 1 September 2017
Compliance with ethical standards
:
: EW, HS, BK, and SD have nothing to disclose. SB has provided consultancy for Blueprint Medicine, Novartis, and Pfizer. DK received honoraria from and provided consultancy for Incyte, Pfizer, and Pharmacyclics. PB held stock in and was an employee of GSK during the time of the study conduct and is now an employee of Novartis Pharma AG. SK was an employee of Novartis Pharmaceuticals Corporation and holds stock in Novartis. YMK was an employee of GlaxoSmithKline (GSK) during the time of study conduct and Novartis Pharmaceuticals Corporation, held GSK stock, and received travel accommodations and expenses from GSK. FF has received research funding from GSK.